RxDoctor Payments Data

Murray Orbuch, MD

Gastroenterology · New York, NYNPI 1245266097

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,460 of the $14,384 with a category attached, or 65.8%. Phathom Pharmaceuticals, Inc. accounts for 81.7% of it on its own, with 8 other manufacturers making up the rest.

$14,384in general payments, 2019–2025

Across 29 payments — averaging $495.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$12K
  • Histosonics, Inc.$2K
  • Intra-sana Laboratories$292
  • E.r. Squibb & Sons, L.L.C.$238
  • GSK$99
  • Pfizer$43
  • plus $53 from 3 others
$152,622in research payments, 2019–2025

Across 51 payments — averaging $2992.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$72K
  • Amgen$31K
  • Eli Lilly$24K
  • Genentech, Inc.$18K
  • Sanofi$9K

What the payments were for

  • Speaking & faculty fees$9,46066%
  • Travel & lodging$3,44024%
  • Food & beverage$1,48410%

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,384 in reported general payments places this provider in the 80th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York →

Medicare billing

Part B allowed, 2024
$17,893
Medicare patients
60
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide14$7,733
Famotidine35$953
Pantoprazole Sodium28$600
Budesonide DrBudesonide12$554
Celecoxib11$173
Levothyroxine Sodium18$17
Amlodipine Besylate16$8

Paid to pharmacies, not to this prescriber.

Other gastroenterology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →